Clin Cancer Res. 2022 Feb 15;28(4):573-575. doi: 10.1158/1078-0432.CCR-21-3949.
Mutations in the gene DNMT3A have been identified in various hematopoietic conditions, including clonal hematopoiesis, myelodysplastic syndrome, and acute myeloid leukemia. The clinical significance of this early mutation and the resultant enhanced clonal fitness have been a focus for therapeutic intervention. See related article by Venugopal et al., p. 756.
DNMT3A 基因突变已在各种造血条件中被发现，包括克隆性造血、骨髓增生异常综合征和急性髓系白血病。这种早期突变及其导致的增强克隆适应性的临床意义一直是治疗干预的重点。见 Venugopal 等人的相关文章，第 756 页。
